Literature DB >> 9893364

Recombinant viruses as vectors for mucosal immunity.

C D Morrow1, M J Novak, D C Ansardi, D C Porter, Z Moldoveanu.   

Abstract

The development and characterization of viral based vaccine vectors is extremely active research field. Much of this work has been facilitated by developments in molecular biology that allow work with large plasmid-based vectors, as well as the use of PCR. Several different vector systems are now available using RNA viruses and DNA viruses. Each vector system has its own strengths and weaknesses. Due to the differences and diversity between the viruses used as vectors, it is doubtful that a single system will be useful for all desired vaccines. However, the further development of existing, as well as potentially new systems, will provide a repertoire for vaccinologists to design the recombinant vaccine which will generate an optimal humoral and immune response for protection against infection or disease caused by pathogens that infect via mucosal surfaces.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9893364     DOI: 10.1007/978-3-642-59951-4_13

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  7 in total

1.  Enhanced immunoglobulin A response and protection against Salmonella enterica serovar typhimurium in the absence of the substance P receptor.

Authors:  Nancy Walters; Theresa Trunkle; Michael Sura; David W Pascual
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.

Authors:  A Seth; I Ourmanov; J E Schmitz; M J Kuroda; M A Lifton; C E Nickerson; L Wyatt; M Carroll; B Moss; D Venzon; N L Letvin; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

Authors:  S Crotty; C J Miller; B L Lohman; M R Neagu; L Compton; D Lu; F X Lü; L Fritts; J D Lifson; R Andino
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Effects of infection with transmissible gastroenteritis virus on concomitant immune responses to dietary and injected antigens.

Authors:  Michael Bailey; Karin Haverson; Bevis Miller; Philip Jones; Isabel Sola; Luis Enjuanes; Christopher R Stokes
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

6.  In vivo phage display to identify M cell-targeting ligands.

Authors:  Lisa M Higgins; Imelda Lambkin; Graham Donnelly; Daragh Byrne; Carolyn Wilson; Jacqueline Dee; Melanie Smith; Daniel J O'Mahony
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.580

Review 7.  Mucosal immunity and tolerance: relevance to vaccine development.

Authors:  C Czerkinsky; F Anjuere; J R McGhee; A George-Chandy; J Holmgren; M P Kieny; K Fujiyashi; J F Mestecky; V Pierrefite-Carle; C Rask; J B Sun
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.